HOME>CSR>Message from the Management

Message from the Management

The Mitsubishi Tanabe Pharma Group believes that its duty to society is to open up the future for patients and for medicine by discovering innovative pharmaceuticals and creating original value. We strive to contribute to the achievement of the 17 Sustainable Development Goals (SDGs) and a sustainable society through the realization of healthy, active lives.

In regard to the advancement of global business activities, we have formulated the Code of Conduct, which includes 13 principles for business activities that comprise our corporate identity, including our Philosophy, Vision, and Corporate Behavior Charter. We have documented our basic policies in each field. The code includes such CSR-related items as working styles, environment and safety, and responsibilities as a corporate citizen. In addition to the Code of Conduct, we have also formulated the Mitsubishi Tanabe Pharma Group Declaration on Corporate Citizenship (2013) and the Environment & Safety Policy (2007 (revised 2017)). Moving forward, we will work to foster harmonious coexistence with local communities in each country and to reduce environmental burdens as we conduct our business activities.

The promotion of working-style reforms has been established as a duty of companies. We have continued to implement activities to establish a work environment that provides opportunities for active careers for diverse human resources, to reform employee working styles, and to promote employee health.

These activities have been highly evaluated by external organizations. We have been certified under such programs as the Ministry of Economy, Trade and Industry's "Outstanding Enterprise in Health and Productivity Management — White 500," which recognizes companies that are implementing especially strong health and productivity management; "the Eruboshi System (highest ranking)," which is based on the Act on Promotion of Women's Participation and Advancement in the Workplace; and the "general business owner conforming to standards (Kurumin mark)" system, which is based on the Next Generation Nurturing Support Measures Promotion Law.

Since the August 2017 launch of Radicava* in the U.S. as a new drug, we have worked to increase accessibility for patients and provided support for the treatment of many patients. In addition, for patients who are seeking treatment, we will implement new drug R&D and actively strive to contribute to treatment.

Moving forward, the Mitsubishi Tanabe Pharma Group will continue to act in accordance with its philosophy, which states that "We contribute to the healthier lives of people around the world through the creation of pharmaceuticals," and its vision, which expresses that "We strive to be a global research-driven pharmaceutical company that is trusted by society." On that basis, we will continue to provide sustained value to patients, society, and employees through our business activities.

* Radicava: A treatment agent for amyotrophic lateral sclerosis (ALS), an intractable disease. Launched as the first new ALS treatment agent in the U.S. in 20 years.

Mitsubishi Tanabe Pharma
President & Representative Director

CSR

CSR
Activities
Report
2018

CSR Activities Report 2018

PDF Download

Mitsubishi
Tanabe
Pharma
Corporate
Report
2018

Corporate Report 2018

PDF Download

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide